Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SymBio Pharmaceuticals's quarterly market cap
declined
from Jun. 2025 (円8,529 Mil) to Sep. 2025 (円6,583 Mil) and
declined
from Sep. 2025 (円6,583 Mil) to Dec. 2025 (円5,353 Mil).
SymBio Pharmaceuticals's annual market cap
declined
from Dec. 2023 (円10,421 Mil) to Dec. 2024 (円9,122 Mil) and
declined
from Dec. 2024 (円9,122 Mil) to Dec. 2025 (円5,353 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. SymBio Pharmaceuticals's Enterprise Value for Today is 円4,180 Mil.
SymBio Pharmaceuticals (TSE:4582) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SymBio Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SymBio Pharmaceuticals Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SymBio Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where SymBio Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
SymBio Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SymBio Pharmaceuticals (TSE:4582) has a Market Cap of 円5,050 Mil as of Jul. 15, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SymBio Pharmaceuticals and its competitors. According to the industry distribution chart, SymBio Pharmaceuticals ranks #762 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 74.4%.
Is SymBio Pharmaceuticals' Market Cap too high?
SymBio Pharmaceuticals' current Market Cap is 円5,050 Mil. Based on the distribution chart, SymBio Pharmaceuticals ranks #762 out of 1024 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, SymBio Pharmaceuticals has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, SymBio Pharmaceuticals ranks #762 out of 1024 companies for Market Cap. This places SymBio Pharmaceuticals in the lower half of its industry. The industry median Market Cap is 211.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 211.96, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SymBio Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Market Cap is 211.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SymBio Pharmaceuticals's current Market Cap is 円5,050 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, SymBio Pharmaceuticals (TSE:4582) is currently considered Modestly Overvalued. The stock's GF Value™ is 円60.82, compared to a current price of 円70.00 — trading 15.1% above its estimated fair value. The current Market Cap is 円5,050 Mil. SymBio Pharmaceuticals' overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For SymBio Pharmaceuticals (TSE:4582), the current Market Cap is 円5,050 Mil as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SymBio Pharmaceuticals (TSE:4582) Overvalued in 2026?
Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued.
The current stock price of 円70.00 is trading 15.1% above its estimated GF Value™ of 円60.82.
GuruFocus considers SymBio Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for TSE:4582:
Market Cap: 円5,050 Mil
GF Value™: 円60.82 vs. price of 円70.00 (15.1% above fair value)
No single metric tells the full story. See the TSE:4582 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
35GF Score
Get the complete analysis for TSE:4582
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4582 has been successfully added to your 
